Johnson and Johnson Pharmaceutical R&D (NJ) Release: Study Suggests That Investigational Drug Paliperidone ER Improves Sleep Onset, Continuity And Duration In Clinical Study Of Schizophrenia Patients With Insomnia

TITUSVILLE, N.J., Sept. 19 /PRNewswire/ -- Paliperidone extended-release (ER) tablets, an investigational, once-daily oral medication for schizophrenia, significantly improved sleep onset, sleep continuity, and duration of sleep in schizophrenia patients diagnosed with schizophrenia- related insomnia when compared with placebo. Data from this study were presented today at the 19th Congress of the European College of Neuropsychopharmacology (ECNP).